Septerna (NASDAQ:SEPN) Releases Quarterly Earnings Results

Septerna (NASDAQ:SEPN) released its earnings results on Monday. The company reported ($0.24) earnings per share for the quarter, FiscalAI reports. Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.

Septerna Trading Up 1.0%

NASDAQ SEPN opened at $29.06 on Tuesday. Septerna has a 1-year low of $4.66 and a 1-year high of $32.63. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -19.25 and a beta of 3.43. The stock’s 50 day moving average is $26.89 and its two-hundred day moving average is $23.14.

Analyst Ratings Changes

SEPN has been the topic of a number of research reports. Wells Fargo & Company boosted their target price on shares of Septerna from $28.00 to $48.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. Wall Street Zen downgraded Septerna from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 10th. Truist Financial began coverage on Septerna in a research report on Monday, December 15th. They set a “buy” rating and a $34.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research note on Thursday, January 22nd. Finally, JonesTrading assumed coverage on Septerna in a research report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $38.00.

Insider Buying and Selling

In other Septerna news, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $28.97, for a total value of $115,880.00. Following the sale, the chief operating officer directly owned 174,209 shares in the company, valued at $5,046,834.73. This represents a 2.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Samira Shaikhly sold 70,453 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $28.10, for a total value of $1,979,729.30. Following the transaction, the insider owned 793 shares of the company’s stock, valued at $22,283.30. This represents a 98.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Septerna

Institutional investors and hedge funds have recently made changes to their positions in the company. Deutsche Bank AG increased its position in shares of Septerna by 5.3% during the 4th quarter. Deutsche Bank AG now owns 14,879 shares of the company’s stock worth $415,000 after purchasing an additional 744 shares in the last quarter. Global Retirement Partners LLC acquired a new position in Septerna in the fourth quarter valued at about $35,000. Covestor Ltd raised its stake in shares of Septerna by 55.8% in the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after acquiring an additional 1,296 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Septerna by 15.0% in the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares during the last quarter. Finally, PharVision Advisers LLC boosted its holdings in shares of Septerna by 17.5% in the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after acquiring an additional 1,780 shares in the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.